Menu
Oncology Evolved
Engineering the Next Generation of Off-the-Shelf Cell Therapies
PIPELINE
PRE-CLINICAL
CLINICAL
CAR-T (Allogeneic)
T-ALL/LBL
WU-CART-007
Memory NK (Allogeneic)
AML
WU-NK-101
Solid Tumors
WU-NK-101 + mAb
Solid Tumors
WU-NK-201 Engineered
LATEST NEWS
Wugen to Present at the Upcoming Jefferies London Healthcare Conference
SAINT LOUIS, MO and SAN DIEGO, CA, November 10, 2022 – Wugen, Inc., a clinical-stage biotechnology company developing a pipeline…
Wugen to Present Data Characterizing WU-NK-101 at The Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting
-- WU-NK-101’s differentiated memory natural killer (NK) expression profile supports enhanced anti-tumor activity and metabolic flexibility -- -- Data support…
Wugen to Present Data on WU-NK-101 for Relapsed / Refractory Acute Myelogenous Leukemia at The American Society of Hematology’s (ASH) 64th Annual Meeting
SAINT LOUIS, MO and SAN DIEGO, CA, November 3, 2022 – Wugen, Inc., a clinical-stage biotechnology company developing a pipeline…
Copyright © 2022 Wugen. All Rights Reserved.
a COGNEO design